Malin Parkler, CEO of Pfizer Sweden, has been appointed new Chair of the Board of the Research-based Pharmaceutical Industry in Sweden (LIF).
Parkler was elected to the Board of LIF in 2014 and she was elected Vice Chair of the Board of LIF in 2018. Since February 2019 she has been the Chair of the LIF Board since the previous Chair, Niklas Karlberg, Novartis, left the Board for an international assignment.
“I am very excited to be able to carry on the development work that LIF successfully has conducted during the last couple of years. LIF is a very important and reliable partner within Swedish healthcare and that is a position that we need to manage well. Sweden needs an international competitive life science strategy where all actors collaborate and interact with each other to develop and ensure that patients quickly and safely have access to effective treatments. A well-functioning ecosystem for research, development and production means both better treatments for patents, development of scientific skills and investments in production,” says Malin Parkler.
Photo of Malin Parkler: Pfizer Sweden
